(Q38232492)

31 August 2017

Antifungal combination therapy for invasive aspergillosis (English)

1 reference

31 August 2017

0 references

Almudena Martín-Peña

1

1 reference

31 August 2017

Manuela Aguilar-Guisado

series ordinal

2

1 reference

31 August 2017

Ildefonso Espigado

series ordinal

3

1 reference

31 August 2017

José Miguel Cisneros

series ordinal

4

1 reference

31 August 2017

language of work or name

English

0 references

publication date

21 July 2014

1 reference

Clinical Infectious Diseases

31 August 2017

1 reference

31 August 2017

59

1 reference

31 August 2017

10

1 reference

31 August 2017

1437-1445

1 reference

Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality

31 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Combination therapy for invasive mycoses: evaluation of past clinical trial designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Combination antifungal therapy for invasive fungal infections in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Clinical practice: combination antifungal therapy for mold infections: much ado about nothing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Efficacy of micafungin alone or in combination against systemic murine aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Combination antifungal therapy for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Cost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU581

21 January 2018

Identifiers

DOI

10.1093/CID/CIU581

1 reference

31 August 2017

1 reference